Silylated biomolecules
US-9285360-B2 · Mar 15, 2016 · US
Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel thereof for treating heart failure
US10632203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10632203-B2 |
| Application number | US-201815949509-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2018 |
| Priority date | Jun 3, 2011 |
| Publication date | Apr 28, 2020 |
| Grant date | Apr 28, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating heart failure including administration by injection into myocardium of an aqueous composition which has a physiological pH, said composition comprising: i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes; and ii) a hydrogel solution comprising from 0.8 to 1.5% w/v of silylated-hydroxypropylmethylcellulose (Si-HPMC) capable of forming a pH dependent self-reticulating hydrogel. 2. The method according to claim 1 , wherein the stem cells are mesenchymal stem cells. 3. The method according to claim 1 , wherein the hydrogel solution (ii) has the following rheological characteristics at a pH value of 7.4 after 3 weeks of reticulation: a compressive modulus at 5% stress from 220 to 430 Pa; a storage modulus (G′) from 235 to 450 Pa; a loss modulus (G″) from 29 to 60 Pa; a gel point from 23.8 to 30.6 minutes. 4. A method of treating heart failure including administration by injection into myocardium of an aqueous composition which has a physiological pH, said composition comprising: i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes; and ii) a hydrogel solution comprising silylated-hydroxypropylmethylcellulose (Si-HPMC), said Si-HPMC being capable of forming a pH dependent self-reticulating hydrogel, wherein the hydrogel solution has the following rheological characteristics at a pH value of 7.4 after 3 weeks of reticulation: a compressive modulus at 5% stress from 220 to 430 Pa; a storage modulus (G′) from 235 to 450 Pa; a loss modulus (G″) from 29 to 60 Pa; a gel point from 23.8 to 30.6 minutes.
Assignees
Inventors
Classifications
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
the cells being hematopoietic, bone marrow derived or blood cells · CPC title
Cellulose · CPC title
- A61K47/38Primary
Cellulose; Derivatives thereof · CPC title
- C12N5/0068Primary
General culture methods using substrates (for specific animal cell type C12N5/06) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10632203B2 cover?
- The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use fo…
- Who is the assignee on this patent?
- Weiss Pierre, Mathieu Eva, Guicheux Jerome, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/38. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).